This is like the most infuriating thing ever for me. Just think about this.. the only way that Amarin loses (very very slightly) is if the tests are conducted and the results show that both products are identical, biologically.
What would Amarin lose? The cost of the study + very few people would switch over.
What are the odds that Generics are identical to Vascepa under the microscope and after a year? Close to 0%, IMO.
On the opposite side of the spectrum, if the results show that the Generics are very different, then it's game over for the Generics.
But if the results are mixed, inconclusive, somewhere in between, we would have a field day with this. We could plant so much doubt (rightfully so), that people and doctors would think twice before switching to Generics. All we would need is a tiny bit of lab data showing they aren't identical.
But without that, we can't do squat and it infuriates the hell out of me.
News 
Market Data 
Discover 
AI
